Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells

Cellular and Molecular Immunology

Volumn 9, Issue 4, 2012, Pages 350-360

  Cetkovic Cvrlje, Marina ^a   Olson, Marin ^a   Ghate, Ketaki ^a  

^a ST CLOUD STATE UNIVERSITY   (United States)

Author keywords

FoxP3; Janus tyrosine kinase 3 (JAK3) inhibition; regulatory T cells (Tregs); TGF ; type 1 diabetes (T1D)

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; JANUS KINASE 3; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; FEMALE; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN;

ANIMALS; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; CYTOPROTECTION; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; JANUS KINASE 3; MICE; MICE, INBRED NOD; QUINAZOLINES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

MURINAE; MUS;

EID: 84863459294     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.20     Document Type: Article

References (55)

1. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T cells can control established type 1 diabetes. Diabetes 2005; 54: 306-310.
2. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006; 212: 217-237.
3. Tang Q, Henriksen KJ, Mingying B, Finger EB, Szot G, Ye J et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 1455-1465.
4. You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 2006; 212: 185-202.
5. Riley RL, June CH, Blazar BR. Human T regulatory cell therapy: Take a billion or so and call me in the morning. J Immunity 2009; 30: 656-665.
6. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Shohei H, Fehervari Z et al. Foxp31CD251CD41 natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
7. Curotto De Lafaille MA, Lafaille JJ. Natural and adaptive Foxp31 regulatory T cells: More of the same or a division of labor? Immunity 2009; 30: 626-635.
8. Workman CJ, Workman-Szymczak AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci 2009; 66: 2603-2622.
9. Ihle JN, Kerr IR. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11: 69-74.
10. Leonard WJ, O'Shea JJ. Jaks and Stats: Biological implications. Annu Rev Immunol 1998; 16: 293-322.
11. Shuai K, Liu B. Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 2003; 3: 900-911.
12. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270: 800-802.
13. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995; 3: 771-782.
14. O'Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004; 41: 727-737.
15. Cetkovic-Cvrlje M, Tibbles HE. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Curr Pharm Des 2004; 10: 176-84.
16. O'Shea J, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555-564.
17. Wilson LJ. Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 2010; 20: 609-623.
18. Xiong Z, Ma A, Chen H. JAK3 inhibitors in organ transplantation and autoimmune disease. Recent Pat Inflamm Allergy Drug Discov 2010; 4: 75-81.
19. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin Cancer Res 1999; 5: 1569-1582.
20. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, Liu XP, Uckun FM. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607-1613.
21. Cetkovic-Cvrlje M, Uckun FM. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases. Arch Immunol Ther Exp 2004; 52: 69-82.
22. Cetkovic-Cvrlje M, Roers BA, Schonhoff D, Waurzyniak B, Liu XP, Uckun FM. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. Leuk Lymphoma 2002; 43: 1447-1553.
23. Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004; 126: 821-827.
24. Cetkovic-Cvrlje M, Dragt AL, Uckun FM. Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with [4-(49- hydroxyphenyl)-Amino-6,7-dimethoxyquinazoline] (JANEX-1). Drug Res 2003; 53: 648-654.
25. Cetkovic-Cvrlje M, Dragt AL, Vassilev A, Liu XP, Uckun FM. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabtes in NOD mice. Clin Immunol 2003; 106: 213-225.
26. Demirkiran A, Hendrikx TK, Baan CC, van Der Laan LJW. Impact of immunosuppressive drugs on CD41CD251FOXP31 regulatory T cells: Does in vitro evidence translate to the clinical setting? Transplantation 2008; 85: 783-789.
27. Bataglia M, Stabilini A, Roncarolo MG. Rapamycin selctively expands CD41CD251FoxP31 regulatory T cells. Blood 2005; 105: 4743-4748.
28. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD41CD251FOXP31 regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-8347.
29. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occuring human CD41CD251FoxP31 regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320-329.
30. Baan CC, van Der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117.
31. Coenen JJ, Koenen HJ, van Rijssen E. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD41CD251FoxP31 regulatory T cells. Bone Marrow Transplant 2007; 39: 537-545.
32. Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect 2003; 16: 277-282.
33. Bensinger SJ, Walsh PT, Zhang J, Caroll M, Parsons R, Rathmell JC et al. Distinct IL-2 receptor signaling pattern in CD41CD251 regulatory T cells. J Immunol 2004; 172: 5287-5296.
34. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
35. Olson M, Johnson S, Cetkovic-Cvrlje M. Incidence of type 1 diabetes in the colony of NOD/LtJ mice at St. Cloud State University. J Mn Acad Science 2008; 71: 24.
36. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliott JF, Leiter EH. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta cell antigens. Diabetes 1997; 46: 1975-1982.
37. Vieira PL, Christensen JR, Minaee S, O'Neil EJ, Barrat FJ, Boonstra A et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occuring CD41CD251 regulatory T cells. J Immunol 2004; 172: 5986-5993.
38. Uckun FM, Ek O, Liu X-P, Chen C-L. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [4-(49-hydroxyphenyl)-Amino-6, 7-dimethoxyquinazoline]. Clin Cancer Res 1999; 5: 2954-2962.
39. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, LitsaDet al. IL-2 regulates FOXP3 expression in human CD41CD251 regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579.
40. Mayack SR, Berg LJ. Cutting edge: An alternative pathway of CD41 T cell differentiation is induced following activation in the absence of gamma-chaindependent cytokine signals. J Immunol 2006; 176: 2059-2063.
41. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W et al. The effect of the JAK inhibitor CP-690, 550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87: 79-86.
42. Rabinovitch A, Suarez-Pinzon WL. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 2007; 48: 159-163.
43. Richer MJ, Straka N, Fang D, Shanina I, Horwitz MS. Regulatory T-cells protect from type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-beta. Diabetes 2008; 57: 1302-1311.
44. Tonkin DR, Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol 2009; 39: 1313-1322.
45. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, Bonifacio E et al. Induction of tolerance in type 1 diabetes via both CD41CD251 T regulatory cells and T regulatory type 1 cells. Diabetes 2006; 55: 1571-1580.
46. Tian B, Hao J, Zhang Y, Tian L, Yi H, O'Brien TD et al. Upregulating CD41CD251FOXP31 regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 2009; 87: 198-206.
47. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD41CD252 naive T cells to CD41CD251 regulatory T cells by TGF-beta induction of transcription factor FoxP3. J Exp Med 2003; 198: 1875-1886.
48. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell population by foreign antigen. Nat Immunol 2005; 6: 1219-1227.
49. Wekerle T. T regulatory cells-what relationship with immunosuppressive agents? Transplant Proc 2008; 40: 13-16.
50. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD41CD251FOXP31 regulatory T cells. Diabetes 2008; 57: 2341-2347.
51. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425-1433.
52. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP31CD41CD251 T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36: 2139-2149.
53. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J et al. Inhibition of CD41CD251 regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
54. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najaflan N. A novel mechanism of action for anti-thymocyte globulin: Induction of CD41CD251Foxp31 regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-2853.
55. Kohm AP, McMahon JS, Podojil JR, Begolka WS, DeGutes M, Kasprowicz DJ et al. Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD41CD251 T regulatory cells. J Immunol 2006; 176: 3301-3305.